The estimated Net Worth of Pratik S Multani is at least $958 Thousand dollars as of 15 December 2023. Dr Multani owns over 14,042 units of Oric Pharmaceuticals stock worth over $288,001 and over the last 11 years he sold ORIC stock worth over $0. In addition, he makes $669,758 as Chief Medical Officer at Oric Pharmaceuticals.
Dr has made over 2 trades of the Oric Pharmaceuticals stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 14,042 units of ORIC stock worth $139,016 on 15 December 2023.
The largest trade he's ever made was exercising 14,042 units of Oric Pharmaceuticals stock on 15 December 2023 worth over $139,016. On average, Dr trades about 1,004 units every 18 days since 2014. As of 15 December 2023 he still owns at least 29,091 units of Oric Pharmaceuticals stock.
You can see the complete history of Dr Multani stock trades at the bottom of the page.
Dr. Pratik S. Multani M.D., M.S. is the Chief Medical Officer at Oric Pharmaceuticals.
As the Chief Medical Officer of Oric Pharmaceuticals, the total compensation of Dr S at Oric Pharmaceuticals is $669,758. There are 1 executives at Oric Pharmaceuticals getting paid more, with Dr. Jacob M. Chacko M.B.A., M.D. having the highest compensation of $790,955.
Dr S is 54, he's been the Chief Medical Officer of Oric Pharmaceuticals since . There are 4 older and 5 younger executives at Oric Pharmaceuticals. The oldest executive at Oric Pharmaceuticals, Inc. is Dr. Richard A. Heyman Ph.D., 64, who is the Co-Founder, Independent Chairman & Member of Scientific Advisory Board.
Pratik's mailing address filed with the SEC is C/O CHIMERIX, INC., 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, NC, 27713.
Over the last 5 years, insiders at Oric Pharmaceuticals have traded over $33,873,532 worth of Oric Pharmaceuticals stock and bought 1,422,500 units worth $12,330,600 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Carl L Gordon, and Peter Svennilson. On average, Oric Pharmaceuticals executives and independent directors trade stock every 29 days with the average trade being worth of $996,237. The most recent stock trade was executed by Lori Anne Kunkel on 3 June 2024, trading 20,500 units of ORIC stock currently worth $76,875.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. The company's product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has collaboration and license agreement with Voronoi, Inc.; and Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Oric Pharmaceuticals executives and other stock owners filed with the SEC include: